KOP Therapeutics
PRECLINICAL DATA PACKAGE

Up to 95% Knockdown.
In Vivo Proof of Concept.

Next-generation sequences produced up to 95% knockdown of target oncogenes in preclinical models. The KOP-101 PC3 xenograft study (Charles River) confirmed statistically significant tumor growth inhibition — biostatistician-confirmed, p=0.049.

0

Cancer Indications

Prostate · Breast · Brain · Ovarian

0

Nucleic-Acid Payload Classes

ASO · siRNA · mRNA

No Observed

Organ Toxicity

Early in vivo preclinical work

IN VIVO DATA

KOP-101 PC3 Xenograft Study — Charles River Laboratories

KOP-101 was evaluated in a nude mouse prostate cancer xenograft model at Charles River Laboratories. Results were analyzed by an independent biostatistician and confirmed statistically significant tumor growth inhibition.

Confirmed

Tumor Growth Inhibition

TGI — treated vs. control

12.7%

Treated Group

Tumor reduction (CI95%: 9.5–15.9)

6.7%

Control Group

Tumor growth (CI95%: 4.1–9.3)

STUDY PARAMETERS

ModelPC3 prostate cancer xenograft (nude mouse)
CROCharles River Laboratories
Statistical AnalysisIndependent biostatistician — final report
p-value0.049 (statistically significant)
Toxicity ObservedNone observed in treated animals
Study TypeGLP-grade in vivo efficacy study

INTERPRETATION

The treated group showed statistically significant tumor growth inhibition compared to the control group. The treated animals exhibited 12.7% tumor reduction while controls grew by 6.7% — a clean, statistically significant differentiation confirmed by independent biostatistician analysis.

SAFETY PROFILE

No toxicity was observed in treated animals throughout the study. The tumor-selective peptide delivery mechanism is designed to minimize off-target exposure to healthy tissue — a key differentiator from systemic RNA delivery platforms.

NEXT MILESTONE

96-Hour Cancer Cell Kill Study

The next planned study will determine ED50 and ED90 values — the effective doses required to kill 50% and 90% of cancer cells. This data is critical for dose optimization and IND-enabling development.

Study Type96-hour cancer cell kill assay
EndpointsED50 / ED90 effective dose determination
CROGalenvs Sciences — Montreal, QC
PurposeDose optimization for IND-enabling studies

Ready to Review the Full Data Package?

Contact our corporate development team to request the complete preclinical data package and partnering deck.

REQUEST DATA PACKAGE VIEW PIPELINE
KOP Therapeutics

Advancing tumor-targeted RNA therapeutics toward IND-enabling development, partnership, and commercialization.

Preclinical Stage

DISCLAIMER

The information contained in this presentation is in summary form only, is not intended to be complete and may contain inadvertent or unintentional errors. No representation, warranty or guarantee, expressed or implied, is made as to the fairness, accuracy or completeness of information contained herein, including the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, results or statements in relation to future matters contained in this presentation. This presentation does not constitute an offer to sell or the solicitation of an offer to buy any security and is not intended to be relied upon as advice to investors or potential investors. KOP is not liable to any recipient or third party for the use of or reliance on the information contained in this presentation.

This communication contains forward-looking statements, which relate to future events or future performance, that are neither promises nor guarantees and are subject to numerous risks and uncertainties that may cause future results to differ materially from those expected and does not constitute an offer to sell or a solicitation of an offer to buy any securities. KOP's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), or any state securities laws and may not be offered or sold within the United States or to or for the account or benefit of a U.S. person (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws or an exemption from such registration is available.

Also, this communication is intended for the sole use of the addressee(s) and may contain confidential, personal and/or privileged information. Unless you are the intended recipient, we ask that you do not retain, disclose, distribute, or take action relying on any information contained herein, and that you please alert us immediately of the erroneous delivery by return e-mail. Any communication received in error, or subsequent reply should be deleted or destroyed. Thank you for your cooperation.

COPYRIGHT AND TRADEMARK

The information in this presentation (including certain names, graphics, logos, icons, designs, words, titles or phrases) is protected by copyright and other laws and may not be copied, reproduced, modified, uploaded, posted, transmitted, or distributed in any way without KOP's prior written approval. Any unauthorized downloading, re-transmission, re-publication or other copying or modification of trademarks and/or the contents herein is strictly prohibited.

© 2026 KOP Therapeutics Inc. All rights reserved.

Montreal, Quebec, Canada · 604.256.9900